Hologic

HOLX · NASDAQ

Price unavailable right now.

No price history for this range.

HOLX analyst rating

HoldConsensus of 10 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold10
Underperform0
Sell0

12-month price target · 16 analysts

Average $76.66

Low: $70.70
High: $81.90

Upgrades and downgrades

The latest rating actions, newest first

HOLX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Argus Research	Jan 12, 2026	Downgrade	Buy → Hold	—	66%
Evercore ISI Group	Jan 5, 2026	Downgrade	Outperform → In-Line	$79.00 → $78.00	52%
Morgan Stanley	Nov 11, 2025	Maintains	Equal-Weight	$69.00 → $76.00	48%
Mizuho	Oct 23, 2025	Downgrade	Outperform → Neutral	$70.00 → $78.00	56%
Raymond James	Oct 22, 2025	Downgrade	Outperform → Market Perform	—	44%
Stephens & Co.	Oct 22, 2025	Downgrade	Overweight → Equal-Weight	$78.00 → $76.00	51%
JP Morgan	Oct 22, 2025	Downgrade	Overweight → Neutral	$78.00	71%
Leerink Partners	Oct 21, 2025	Maintains	Market Perform	$70.00 → $78.00	51%
BTIG	Oct 21, 2025	Maintains	Neutral	—	48%
Needham	Oct 21, 2025	Maintains	Hold	—	45%

The case for and against

Updated Apr 3, 2026

Bull case

Hologic is positioned for a strong financial outlook, primarily driven by anticipated organic revenue growth of 5-7% due to robust procedure volume growth, new product launches, and strategic acquisitions in its Diagnostics and Breast Health segments. The company’s bull case scenario suggests further revenue acceleration into the high-single digits (7-9%), supported by improved operating margins and a strong balance sheet with limited leverage. Additionally, Hologic's emphasis on margin expansion and operational efficiencies indicates a projection of 8-12% earnings growth, highlighting the firm's overall positive trajectory in its core healthcare markets.

Bear case

The financial outlook for Hologic is adversely impacted by anticipated revenue growth slowing to the low-single digits (1-4%), primarily due to weakness in its Diagnostics and Breast Health segments. Despite recent mergers and acquisitions aimed at expanding its asset base, the company has struggled to re-accelerate its top-line growth post-COVID, compounded by risks such as a weak global economy and increased competition in key markets. Consequently, Hologic's operating margins are expected to remain capped in the low-30s, limiting the potential for significant earnings per share growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.